220 results on '"Barbieri, Fausto"'
Search Results
2. Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy
3. Treating cancer with immunotherapy in HIV-positive patients: A challenging reality
4. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
5. Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
6. Are we ready to describe response or progression to immunotherapy in lung cancer?
7. Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal
8. Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
9. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
10. Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
11. Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study
12. Chemotherapy in Thymic Neoplasms
13. Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres
14. Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups
15. Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: a single institutional retrospective report
16. Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy
17. Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations
18. Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas
19. Squamous Cell Carcinoma “Transformation” Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas
20. Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy
21. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
22. Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: a case report
23. Supplementary_Material_-_online_only – Supplemental material for Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
24. Informal Caregiving Burden in Advanced Non-small Cell Lung Cancer: The HABIT study
25. Primary Lung Cancer Presenting with Gastrointestinal Tract Involvement: Clinicopathologic and Immunohistochemical Features in a Series of 18 Consecutive Cases
26. A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
27. Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients
28. BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience
29. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
30. Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small lung cancER with central Malignant airway Obstructions: a multicentric REtrospective study (EVERMORE)
31. First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
32. Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
33. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients
34. Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
35. Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
36. Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non–Small-Cell Lung Cancer: Results of a Phase II-III Study
37. A PARALLEL RANDOMIZED PHASE II TRIAL EVALUATING STANDARD VERSUS PROLONGED INFUSION GEMCITABINE (G) AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
38. Paclitaxel / carboplatin (PC) vs paclitaxel / carboplatin / gemcitabine (PCG) in advanced NSCLC: Preliminary results of a phase II-III study
39. Supplemental_Information – Supplemental material for Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program
40. Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma
41. Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report
42. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program
43. BRAF mutations in sarcomatoid and large cell carcinoma of the lung
44. The role of surgery in the multimodal treatment of primary gastric non-Hodgkin's lymphomas: a report of 76 cases and review of the literature
45. Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis
46. Late Gastrointestinal Toxicity During Nivolumab Therapy in Non–Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease
47. Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy.
48. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients. Results from a multicenter Italian observational study
49. Large cell neuroendocrine carcinoma of the lung: chemotherapy regimen depends on how “large” your diagnostic criteria are
50. Secondary biopsy of non-oncogenic-driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.